TrumpRx

A majority of Americans prioritize healthcare affordability in their voting decisions, with bipartisan support for policies like direct-to-consumer drug sales and expanded prescription drug discounts. The Axios-Ipsos poll highlights a partisan divide over reinstating Affordable Care Act subsidies, which could influence the 2022 midterms as economic pressures intersect with healthcare costs.

President Trump announced that the TrumpRx list has expanded to include more than 800 drugs. The TrumpRx site now lists over 800 drugs, according to the president.

President Trump announced that over 800 drugs are now listed on the TrumpRx platform. The platform's drug list has been expanded again.

President Trump announced the expansion of TrumpRx, adding 160 prescription drugs at discounted prices, bringing the total to over 800. This is the second expansion of the initiative in two months.

President Trump announced the expansion of TrumpRx, adding 160 prescription drugs at highly discounted prices, increasing the total to over 800 medications. The initiative is part of the administration’s direct-to-consumer drug platform.

Cigna will stop covering GLP-1 weight loss drugs like Wegovy and Zepbound in its employee health plan starting July 1, directing users to cash-pay options. A study suggests long-term use of GLP-1 drugs could reduce knee replacement risk by up to 5% over eight years. Prices for these drugs are declining in 2026 with new oral versions.

Dr. Mehmet Oz, head of the Centers for Medicare & Medicaid Services, avoided answering questions during a White House briefing about Bill Pulte's nomination to lead national intelligence, stating the topic was 'out of my lane.' The White House has been using various officials for briefings while press secretary Karoline Leavitt is on maternity leave, with Oz focusing on healthcare updates like adding medications to the TrumpRx website.

The article outlines three steps to reduce healthcare costs and fraud in the U.S., including providing patients with upfront pricing through the Advanced Explanation of Benefits (AEOB) and reforming the Federal Employees Health Benefits Program. It criticizes the Biden administration for not implementing the AEOB and highlights President Trump's TrumpRX platform as a model for transparency.

Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, mocked Joy Behar on social media after she warned that Americans would "all going to die" if Trump's name was attached to the new TrumpRx prescription drug plan. The exchange escalated tensions on "The View" where co-hosts debated the merits and trustworthiness of the drug-pricing initiative, with some supporting it for lower costs regardless of branding and others expressing skepticism based on Trump's past business ventures.

The View co-hosts debated President Donald Trump's TrumpRx initiative, a plan to lower prescription drug costs, with some expressing skepticism due to Trump's involvement. Joy Behar warned that the plan could have negative consequences, while others argued it could bring down prescription drug costs. The plan partners with private-sector companies like Amazon and Mark Cuban Cost Plus Drugs.

Sen. Bill Cassidy's primary loss is a win for MAHA, and there are multiple changes in dynamics that could affect health secretary Robert F. Kennedy Jr. and the Trump administration. TrumpRx adds generic drugs. The loss is one of several changes that may make life easier or harder for the administration.

The US Supreme Court declined to hear lawsuits from brand-name pharmaceutical companies against the Medicare drug price negotiation program, and the TrumpRx prescription drug discount platform is expanding with over 600 generic drugs. The expansion is a result of partnerships with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx. This development may make remaining legal challenges more difficult for the drug industry.

President Trump announced the addition of over 600 generic drugs to his drug coupon platform TrumpRx, increasing the number of available drugs by nearly seven times. Mark Cuban joined President Trump to endorse the website. The expansion aims to provide more affordable generics through the platform.

Donald Trump announced an expansion of his prescription drug website, TrumpRx, increasing the number of medications available via the discount program nearly sevenfold to over 600. The expansion aims to increase accessibility to prescription drugs. Experts previously questioned the site's limited offerings.

The White House has expanded its prescription drug discount platform, TrumpRx, by adding over 600 generic drugs through partnerships with Cost Plus Drug Co, Amazon Pharmacy, and GoodRx. This expansion aims to provide consumers with a single source for low-cost prescriptions. The partnership is expected to benefit consumers by offering them the lowest possible cost on their prescriptions.

The White House has added over 600 generic drugs to the TrumpRx site, increasing the number of products on the platform by nearly seven times. This expansion is part of an effort to increase access to affordable medications. The move aims to provide consumers with more direct-to-consumer options.

President Trump is expected to announce an expansion of discounted prescription drugs through TrumpRX at a White House event. The announcement comes after a summit with China and amidst ongoing tensions with Iran. The move aims to address affordability concerns.

KFF Health News chief Washington correspondent Julie Rovner discussed federal policy on vaccine research and vaping, while editor-at-large Céline Gounder talked about rising drug prices despite TrumpRx hopes. Rovner also covered the Supreme Court decision on the abortion pill mifepristone. These discussions were featured on various news programs.

17 pharmaceutical companies spent over $130 million on federal lobbying in 2025, a 23% surge, as the TrumpRx prescription drug-pricing program was being shaped. Eli Lilly paused its obesity awareness campaign in India after the nation's drugs regulator warned of potential rule violations. The campaign aimed to reframe obesity as a chronic disease.

The TrumpRx program connects consumers with discount coupons from drugmakers, but using these coupons can be problematic for insured patients. This is because coupons can lead to hidden costs. The program's implications are still being assessed.

Prescription drug coupons offered by manufacturers may have hidden costs, especially for people with insurance, and their use has slowed down in recent years despite rising prescription drug costs. Patients without insurance can save money using these coupons, but they have limitations and guidelines. The decision to accept a coupon is complicated and depends on individual circumstances.

Johnson & Johnson will begin marketing four of its prescription drugs on the Trump administration's TrumpRx website. The move is part of the Trump administration's initiative to promote affordable medications through the TrumpRx platform.

President Donald Trump announced a deal with Regeneron Pharmaceuticals to lower drug prices under the most-favored-nation initiative, including discounted Medicaid pricing and a $225 price for cholesterol drug Praluent on the TrumpRx website. The agreement, part of broader efforts to reduce healthcare costs ahead of midterms, also includes $27 billion in U.S. R&D investments and expedited FDA approval for Regeneron's gene therapy.

President Trump announced a drug pricing deal with Regeneron, the 17th pharmaceutical company to agree to his 'most favored nation' policy, lowering prices for Medicaid and cash-paying patients. Critics question the impact of the confidential agreements, as discounts may not affect most Americans on private insurance or Medicare.

Mark Cuban, billionaire investor and owner of CostPlusDrugs.com, rejected a presidential bid and announced collaboration with the Trump administration's TrumpRx initiative to reduce healthcare costs. His platform aims to lower drug prices by eliminating middlemen and importing generic medications to Dallas, significantly benefiting patients with chronic illnesses.

A report found that drugmakers increased prices on hundreds of drugs despite President Trump's TrumpRx initiative aimed at reducing costs. Trump had announced the program in February 2020, but the analysis revealed ongoing price hikes by pharmaceutical companies.